metformin has been researched along with oxyntomodulin in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (8.20) | 29.6817 |
| 2010's | 38 (62.30) | 24.3611 |
| 2020's | 18 (29.51) | 2.80 |
| Authors | Studies |
|---|---|
| Bardini, G; Ciani, S; Cremasco, F; Mannucci, E; Mencucci, A; Messeri, G; Ognibene, A; Pierazzuoli, E; Rotella, CM | 1 |
| Holst, JJ; Madsbad, S; Taskiran, M; Toft-Nielsen, MB; Zander, M | 1 |
| Brazg, R; D'Alessio, DA; Ehlers, MR; Harley, RE; Kay, HD; Klaff, LJ; Mathisen, AL; Schneider, R | 1 |
| Hamann, A; Morcos, M; Nawroth, P | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Barrington, P; Chien, JY; Cui, S; Ellis, B; Hardy, TA; Schneck, K; Showalter, HD; Tibaldi, F | 1 |
| Bakris, GL; Flynn, C | 1 |
| Guerci, B; Milicevic, Z; Nauck, M; Skrivanek, Z; Umpierrez, GE; Weinstock, RS | 1 |
| Anderson, JH; Berry, D; Berry, S; Chien, JY; Forst, T; Gaydos, BL; Geiger, MJ; Heathman, MA; Milicevic, Z; Skrivanek, Z | 1 |
| Pechtner, V; Pérez Manghi, F; Shurzinske, L; Tofé Povedano, S; Umpierrez, G | 1 |
| Arakaki, R; Atisso, C; Blevins, T; Colon, G; Garcia, P; Kuhstoss, D; Lakshmanan, M; Wysham, C | 1 |
| Atisso, C; Dungan, KM; Fahrbach, JL; Forst, T; González, JG; Povedano, ST; Sealls, W | 1 |
| Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G | 1 |
| Thompson, AM; Trujillo, JM | 1 |
| Guerci, B; Milicevic, Z; Nauck, MA; Skrivanek, Z; Umpierrez, G; Weinstock, RS | 1 |
| Benroubi, M; Giorgino, F; Pechtner, V; Sun, JH; Zimmermann, AG | 1 |
| Lakshmanan, M; Pechtner, V; Reaney, M; van Brunt, K; Yu, M | 1 |
| Dungan, KM; Fahrbach, JL; Raz, I; Sealls, W; Skrivanek, Z | 1 |
| Athanasiadou, E; Bekiari, E; Boura, P; Karagiannis, T; Liakos, A; Mainou, M; Matthews, DR; Paschos, P; Rika, M; Tsapas, A; Vasilakou, D | 1 |
| Solis-Herrera, C; Triplitt, C | 1 |
| Tong, N; Zhang, L; Zhang, M; Zhang, Y | 1 |
| de la Peña, A; Del Prato, S; Karanikas, CA; Ludvik, B; Mari, A; Milicevic, Z; Pechtner, V; Shurzinske, L | 1 |
| Botros, FT; D'Alessio, D; Guerci, B; Jia, N; Wysham, C | 1 |
| Li, ZX; Sun, F; Wu, SS; Yang, ZR; Zhan, SY | 1 |
| Anglin, G; Barkin, JS; Frossard, JL; Harper, KD; Hensley, IE; Milicevic, Z; Nauck, MA | 1 |
| Aroda, VR; Axelsen, M; Bain, SC; Cariou, B; DeVries, JH; Piletič, M; Rose, L; Rowe, E | 1 |
| Anderson, TW; Derving Karsbøl, J; Golor, G; Hausner, H; Holst, AG; Jacobsen, JB; Wagner, FD | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Kokkinos, A; Liatis, S; Liberopoulos, E; Tentolouris, N | 1 |
| Carmona-Nimo, E; Castilla-Guerra, L; Fernandez-Moreno, MDC; Leon-Jimenez, D | 1 |
| Pace, E; Tingen, J | 1 |
| Boye, KS; Brunt, KV; Milicevic, Z; Varnado, O; Yu, M | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Druyts, E; Kanters, S; Lopes, S; Popoff, E; Sharma, R; Vrazic, H; Wilkinson, L | 2 |
| Filippova, E; Gu, L; Li, P; Nevárez, L; Song, KH; Tao, B; Wang, F; Wang, W; Yang, J | 1 |
| Arechavaleta, R; Bain, SC; Bogdański, P; Comlekci, A; Consoli, A; Deerochanawong, C; Dungan, K; Faingold, MC; Farkouh, ME; Franco, DR; Gram, J; Guja, C; Husain, M; Jeppesen, OK; Joshi, P; Malek, R; Merino-Torres, JF; Mosenzon, O; Nauck, MA; Pedersen, SD; Sheu, WH; Silver, RJ; Strange, M; Tack, CJ; Tandon, N; Thomsen, M | 1 |
| Allison, D; Birkenfeld, AL; Blicher, TM; Davies, M; Deenadayalan, S; Jacobsen, JB; Rosenstock, J; Serusclat, P; Violante, R; Watada, H | 1 |
| Hirsch, IB | 1 |
| Anderson, TW; Borregaard, J; Bækdal, TA; Hansen, CW; Thomsen, M | 1 |
| Bartaskova, D; Cox, DA; Frias, JP; Li, YG; Matyjaszek-Matuszek, B; Milicevic, Z; Tham, LS; Woodward, B; Wynne, AG | 1 |
| Lipscombe, LL | 1 |
| Araki, E; Aroda, VR; Buse, JB; Cariou, B; Harris, SB; Hoff, ST; Pedersen, KB; Tarp-Johansen, MJ; Zinman, B | 1 |
| Capehorn, MS; Catarig, AM; Furberg, JK; Janez, A; Marre, M; Price, HC; Tadayon, S; Vergès, B | 1 |
| Scheen, AJ | 1 |
| Bain, SC; Chudleigh, RA | 1 |
| Del Prato, S; Derwahl, M; Kang, J; Sorli, CH; Soto, A; Stewart, J; Trautmann, ME; Yoon, KH | 1 |
| Capehorn, MS; Catarig, AM; Johansen, P; Lawson, J; Lingvay, I; Paine, A; Sandberg, A; Shaw, R | 1 |
| Piszczatoski, C; Powell, J; Taylor, JR | 1 |
| Alsumali, A; Briggs, A; Davies, G; Kowal, S; Lautsch, D; Li, Q; Rajpathak, S; Wehler, E | 1 |
| Avezum, A; Basile, JN; Colhoun, HM; Cushman, WC; Dagenais, GR; Diaz, R; Dyal, L; Ferrannini, G; Gerstein, H; Jansky, P; Keltai, M; Lakshmanan, M; Lanas, F; Leiter, LA; Lopez-Jaramillo, P; Mellbin, L; Pais, P; Pīrāgs, V; Pogosova, N; Probstfield, J; Raubenheimer, PJ; Riddle, MC; Rydén, L; Shaw, JE; Sheu, WH | 1 |
| Bergman, BK; Brown, K; Cui, X; Davies, MJ; Fernández Landó, L; Frías, JP; Liu, B; Pérez Manghi, FC; Rosenstock, J | 1 |
| Gallwitz, B; Giorgino, F | 1 |
| Shaughnessy, AF | 1 |
| Aragona, M; Daniele, G; Dardano, A; Del Prato, S; Miccoli, R | 1 |
| Bech, PG; Fridhammar, A; Liu, A; Miresashvili, N; Nilsson, A; Stafford, S; Willis, M | 1 |
| Bain, S; Consoli, A; De Remigis, A; Husain, M; Pettersson Meyer, AS; Rasmussen, S | 1 |
| Jacob, S; Kaltoft, MS; Kellerer, M; Lawson, J; Nielsen, LL; Strojek, K; Tabak, Ö | 1 |
| Cheng, AY; Hoog, M; Levine, JA; Mody, R; Pantalone, KM; Patel, H; Sapin, H; Vadher, K | 1 |
| Arslanian, SA; Barrientos-Pérez, M; Bismuth, E; Boucher-Berry, C; Chao, LC; Cho, JI; Cox, D; Dib, S; Hannon, T; Zeitler, P | 1 |
| Chen, M; Li, Y; Xie, D; Xu, M; Zhao, X | 1 |
| Aroda, VR; Baek, S; Choi, J; Denkel, K; Espinasse, M; Frias, JP; Guo, H; Ji, L; Lingvay, I; Nguyên-Pascal, ML; Niemoeller, E | 1 |
20 review(s) available for metformin and oxyntomodulin
| Article | Year |
|---|---|
[Oral diabetes treatment. Which substance is indicated at which time?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Germany; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Obesity; Peptide Fragments; Peptides; Practice Guidelines as Topic; Practice Patterns, Physicians'; Treatment Outcome | 2004 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Male; Metformin; Middle Aged; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms; Weight Gain | 2016 |
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Incretins; Male; Metformin; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Venoms | 2015 |
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Recombinant Fusion Proteins; Risk Factors; Venoms | 2015 |
Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Glargine; Liraglutide; Metformin; Patient Safety; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms | 2016 |
[Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Nasopharyngitis; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Respiratory Tract Infections; Thiazolidinediones; Venoms | 2016 |
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
Topics: Benzhydryl Compounds; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Pioglitazone; Sodium-Glucose Transporter 2 | 2018 |
Antidiabetic drugs and stroke risk. Current evidence.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Thiazolidinediones | 2018 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
Topics: Benzhydryl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Renal Insufficiency, Chronic | 2020 |
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Topics: Administration, Oral; Body Weight; Cardiovascular Diseases; Comorbidity; Decision Making; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Hemoglobins; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Liver; Metformin; Obesity; Renal Insufficiency, Chronic; Research Design; Risk; Stomach | 2021 |
SGLT2 Inhibitors or GLP-1 Receptor Agonists Reduce Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Patient Reported Outcome Measures; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin | 2022 |
29 trial(s) available for metformin and oxyntomodulin
| Article | Year |
|---|---|
Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.
Topics: Adolescent; Adult; Blood Glucose; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Obesity; Peptide Fragments; Peptides | 2001 |
Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Infusions, Parenteral; Insulin; Insulin Secretion; Kinetics; Male; Metformin; Middle Aged; Peptide Fragments; Placebos; Research Design | 2001 |
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Insulin; Metformin; Peptide Fragments; Placebos; Recombinant Proteins; Sulfonylurea Compounds | 2003 |
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Postprandial Period; Recombinant Fusion Proteins; Thiazolidinediones; Treatment Outcome | 2011 |
Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Pyrazines; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2014 |
Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Diet, Reducing; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exercise; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hyperglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Injections, Subcutaneous; Male; Metformin; Middle Aged; Overweight; Receptors, Glucagon; Recombinant Fusion Proteins; Young Adult | 2014 |
Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptides; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Recombinant Fusion Proteins; Thiazolidinediones; Venoms | 2014 |
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Topics: Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Treatment Outcome | 2014 |
Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Weight Loss | 2015 |
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Sulfonylurea Compounds; Treatment Outcome; Weight Loss | 2015 |
Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.
Topics: Adult; Diabetes Mellitus; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Patient Satisfaction; Peptides; Recombinant Fusion Proteins; Surveys and Questionnaires; Time Factors; Venoms | 2015 |
Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Fasting; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Treatment Outcome; Young Adult | 2016 |
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mul
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Insulin Glargine; Male; Metformin; Middle Aged | 2017 |
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
Topics: Adolescent; Adult; Atorvastatin; Cross-Over Studies; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Warfarin; Young Adult | 2017 |
Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Recombinant Fusion Proteins | 2017 |
Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
Topics: Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Mexico; Middle Aged; Recombinant Fusion Proteins; Republic of Korea; Russia; Sulfonylurea Compounds; Treatment Outcome | 2019 |
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cardiovascular Diseases; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Renal Insufficiency, Chronic | 2019 |
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds | 2019 |
Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects.
Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Caprylates; Cardiotonic Agents; Case-Control Studies; Cross-Over Studies; Digoxin; Drug Interactions; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Lisinopril; Male; Metformin; Middle Aged; Warfarin | 2019 |
Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Treatment Outcome; Weight Loss | 2019 |
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Nausea; Treatment Outcome; Weight Loss | 2019 |
Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Treatment Outcome | 2020 |
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Proline; Treatment Outcome | 2020 |
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin.
Topics: Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Recombinant Fusion Proteins; Treatment Outcome; Vascular Diseases | 2021 |
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Male; Metformin; Middle Aged; Nausea; Weight Loss | 2021 |
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
Topics: Canada; Canagliflozin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years | 2022 |
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Aspart; Insulin Glargine; Metformin; Treatment Outcome | 2022 |
Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Injections, Subcutaneous; Insulins; Metformin; Recombinant Fusion Proteins; Treatment Outcome | 2022 |
12 other study(ies) available for metformin and oxyntomodulin
| Article | Year |
|---|---|
Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Recombinant Fusion Proteins; Treatment Outcome | 2016 |
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Recombinant Fusion Proteins; Sitagliptin Phosphate; Venoms | 2017 |
Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Recombinant Fusion Proteins; Treatment Outcome; Weight Loss | 2017 |
The Future of the GLP-1 Receptor Agonists.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate | 2019 |
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Metformin; Sitagliptin Phosphate | 2019 |
SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Metformin; Sodium-Glucose Transporter 2 | 2019 |
Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors | 2020 |
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Topics: Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sitagliptin Phosphate | 2021 |
Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glucose; Glycated Hemoglobin; Heart Disease Risk Factors; HIV Infections; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Linagliptin; Metformin; Middle Aged; Quality of Life; Recombinant Fusion Proteins; Risk Factors; Sepsis | 2022 |
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
Topics: Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Treatment Outcome | 2022 |
Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.
Topics: Ankle Brachial Index; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Elasticity; Endothelial Progenitor Cells; Glucagon-Like Peptides; Glycation End Products, Advanced; Humans; Immunoglobulin Fc Fragments; Interleukin-6; Metformin; Nitric Oxide; Pulse Wave Analysis; Recombinant Fusion Proteins; Tumor Necrosis Factor-alpha | 2022 |
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Treatment Outcome | 2023 |